SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Acadia Pharmaceuticals Inc. – ‘10-Q’ for 9/30/20 – ‘EX-101.SCH’

On:  Wednesday, 11/4/20, at 5:04pm ET   ·   For:  9/30/20   ·   Accession #:  1564590-20-50566   ·   File #:  0-50768

Previous ‘10-Q’:  ‘10-Q’ on 8/6/20 for 6/30/20   ·   Next:  ‘10-Q’ on 5/6/21 for 3/31/21   ·   Latest:  ‘10-Q’ on 11/3/23 for 9/30/23   ·   8 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/04/20  Acadia Pharmaceuticals Inc.       10-Q        9/30/20   60:7.1M                                   ActiveDisclosure/FA

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    897K 
 2: EX-10.1     Material Contract                                   HTML     40K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 6: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
13: R1          Document and Entity Information                     HTML     71K 
14: R2          Condensed Consolidated Balance Sheets               HTML    102K 
15: R3          Condensed Consolidated Balance Sheets               HTML     36K 
                (Parenthetical)                                                  
16: R4          Condensed Consolidated Statements of Operations     HTML     71K 
                (Unaudited)                                                      
17: R5          Condensed Consolidated Statements of Comprehensive  HTML     38K 
                Loss                                                             
18: R6          Condensed Consolidated Statements of Cash Flows     HTML    106K 
                (Unaudited)                                                      
19: R7          Condensed Consolidated Statements of Stockholders'  HTML     60K 
                Equity (Unaudited)                                               
20: R8          Organization and Business                           HTML     22K 
21: R9          Basis of Presentation and Significant Accounting    HTML     60K 
                Policies                                                         
22: R10         Net Loss Per Share                                  HTML     22K 
23: R11         Stock-Based Compensation                            HTML     55K 
24: R12         Balance Sheet Details                               HTML     69K 
25: R13         Investments                                         HTML    226K 
26: R14         Fair Value Measurements                             HTML    138K 
27: R15         Stockholders' Equity                                HTML     23K 
28: R16         Commitments and Contingencies                       HTML     46K 
29: R17         Recent Accounting Pronouncements                    HTML     26K 
30: R18         Leases                                              HTML    105K 
31: R19         Basis of Presentation and Significant Accounting    HTML     79K 
                Policies (Policies)                                              
32: R20         Basis of Presentation and Significant Accounting    HTML     50K 
                Policies (Tables)                                                
33: R21         Stock-Based Compensation (Tables)                   HTML     56K 
34: R22         Balance Sheet Details (Tables)                      HTML     71K 
35: R23         Investments (Tables)                                HTML    221K 
36: R24         Fair Value Measurements (Tables)                    HTML    134K 
37: R25         Leases (Tables)                                     HTML    108K 
38: R26         Basis of Presentation and Significant Accounting    HTML     29K 
                Policies - Schedule of Reconciliation of Cash,                   
                Cash Equivalents and Restricted Cash (Detail)                    
39: R27         Basis of Presentation and Significant Accounting    HTML     30K 
                Policies - Additional Information (Detail)                       
40: R28         Net Loss Per Share - Additional Information         HTML     21K 
                (Detail)                                                         
41: R29         Stock-Based Compensation - Summary of Stock-based   HTML     30K 
                Compensation Expense Included in Statements of                   
                Operations (Detail)                                              
42: R30         Balance Sheet Details - Schedule of Inventory       HTML     28K 
                (Detail)                                                         
43: R31         Balance Sheet Details - Schedule of Accrued         HTML     37K 
                Liabilities (Detail)                                             
44: R32         Investments - Carrying Value and Amortized Cost of  HTML     60K 
                Company's Investments Summarized by Major Security               
                Type (Detail)                                                    
45: R33         Investments - Carrying Value and Amortized Cost of  HTML     23K 
                Company's Investments Summarized by Major Security               
                Type (Parenthetical) (Detail)                                    
46: R34         Investments - Additional Information (Detail)       HTML     25K 
47: R35         Investments - Summary of Gross Unrealized Losses    HTML     38K 
                and Fair Value of Available-For-Sale Investment                  
                Securities in Unrealized Loss Position (Detail)                  
48: R36         Investments - Summary of Gross Unrealized Losses    HTML     23K 
                and Fair Value of Available-For-Sale Investment                  
                Securities in Unrealized Loss Position                           
                (Parenthetical) (Detail)                                         
49: R37         Fair Value Measurements - Fair Value Measurements   HTML     47K 
                of Cash Equivalents, Available-For-Sale Investment               
                Securities and Equity Securities (Detail)                        
50: R38         Stockholders' Equity - Additional Information       HTML     34K 
                (Detail)                                                         
51: R39         Commitments and Contingencies - Additional          HTML     94K 
                Information (Detail)                                             
52: R40         Leases - Additional Information (Detail)            HTML     62K 
53: R41         Leases - Summary of Operating Lease Costs (Detail)  HTML     21K 
54: R42         Leases - Supplemental Cash Flow Information         HTML     23K 
                Related to the Company's Leases (Detail)                         
55: R43         Leases - Summary of Balance Sheet Classification    HTML     27K 
                of Lease Liabilities (Detail)                                    
56: R44         Leases - Summary of Maturities of Lease             HTML     40K 
                Liabilities (Detail)                                             
58: XML         IDEA XML File -- Filing Summary                      XML    105K 
12: XML         XBRL Instance -- acad-10q_20200930_htm               XML   1.71M 
57: EXCEL       IDEA Workbook of Financial Reports                  XLSX     63K 
 8: EX-101.CAL  XBRL Calculations -- acad-20200930_cal               XML    153K 
 9: EX-101.DEF  XBRL Definitions -- acad-20200930_def                XML    256K 
10: EX-101.LAB  XBRL Labels -- acad-20200930_lab                     XML    774K 
11: EX-101.PRE  XBRL Presentations -- acad-20200930_pre              XML    566K 
 7: EX-101.SCH  XBRL Schema -- acad-20200930                         XSD    117K 
59: JSON        XBRL Instance as JSON Data -- MetaLinks              251±   389K 
60: ZIP         XBRL Zipped Folder -- 0001564590-20-050566-xbrl      Zip    198K

‘EX-101.SCH’   —   XBRL Schema — acad-20200930

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date : 2020-11-03T19:22:56.4428275+00:00 -->
<!-- Version : 5.0.1.513 -->
<!-- Package ID : 5ac444499153425cb04478ad18052835 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:acad="http://www.acadia-pharm.com/20200930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.acadia-pharm.com/20200930" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
<xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
<xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
<xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31"/>
<xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric"/>
<xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31"/>
<xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"/>
<xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated"/>
<xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31"/>
<xsd:annotation>
<xsd:appinfo>
<link:roleType id="TemplateLink" roleURI="http://www.acadia-pharm.com/20200930/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
<link:definition> 00000 - Document - Template Link </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple"/>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
<link:definition> 100000 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
<link:definition> 100010 - Statement - Condensed Consolidated Balance Sheets </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
<link:definition> 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
<link:definition> 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
<link:definition> 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition> 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
<link:definition> 100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureOrganizationAndBusiness" id="Role_DisclosureOrganizationAndBusiness">
<link:definition> 100070 - Disclosure - Organization and Business </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
<link:definition> 100080 - Disclosure - Basis of Presentation and Significant Accounting Policies </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
<link:definition> 100090 - Disclosure - Net Loss Per Share </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
<link:definition> 100100 - Disclosure - Stock-Based Compensation </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
<link:definition> 100110 - Disclosure - Balance Sheet Details </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureInvestments" id="Role_DisclosureInvestments">
<link:definition> 100120 - Disclosure - Investments </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
<link:definition> 100130 - Disclosure - Fair Value Measurements </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
<link:definition> 100140 - Disclosure - Stockholders' Equity </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
<link:definition> 100150 - Disclosure - Commitments and Contingencies </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureRecentAccountingPronouncements" id="Role_DisclosureRecentAccountingPronouncements">
<link:definition> 100160 - Disclosure - Recent Accounting Pronouncements </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
<link:definition> 100170 - Disclosure - Leases </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
<link:definition> 100180 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables">
<link:definition> 100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
<link:definition> 100200 - Disclosure - Stock-Based Compensation (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
<link:definition> 100210 - Disclosure - Balance Sheet Details (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
<link:definition> 100220 - Disclosure - Investments (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
<link:definition> 100230 - Disclosure - Fair Value Measurements (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
<link:definition> 100240 - Disclosure - Leases (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
<link:definition> 100250 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition> 100260 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" id="Role_DisclosureNetLossPerShareAdditionalInformationDetail">
<link:definition> 100270 - Disclosure - Net Loss Per Share - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludedInStatementsOfOperationsDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseIncludedInStatementsOfOperationsDetail">
<link:definition> 100280 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense Included in Statements of Operations (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetail" id="Role_DisclosureBalanceSheetDetailsScheduleOfInventoryDetail">
<link:definition> 100290 - Disclosure - Balance Sheet Details - Schedule of Inventory (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetail" id="Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetail">
<link:definition> 100300 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfCompanySInvestmentsSummarizedByMajorSecurityTypeDetail" id="Role_DisclosureInvestmentsCarryingValueAndAmortizedCostOfCompanySInvestmentsSummarizedByMajorSecurityTypeDetail">
<link:definition> 100310 - Disclosure - Investments - Carrying Value and Amortized Cost of Company's Investments Summarized by Major Security Type (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfCompanySInvestmentsSummarizedByMajorSecurityTypeParentheticalDetail" id="Role_DisclosureInvestmentsCarryingValueAndAmortizedCostOfCompanySInvestmentsSummarizedByMajorSecurityTypeParentheticalDetail">
<link:definition> 100320 - Disclosure - Investments - Carrying Value and Amortized Cost of Company's Investments Summarized by Major Security Type (Parenthetical) (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetail" id="Role_DisclosureInvestmentsAdditionalInformationDetail">
<link:definition> 100330 - Disclosure - Investments - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfGrossUnrealizedLossesAndFairValueOfAvailableForSaleInvestmentSecuritiesInUnrealizedLossPositionDetail" id="Role_DisclosureInvestmentsSummaryOfGrossUnrealizedLossesAndFairValueOfAvailableForSaleInvestmentSecuritiesInUnrealizedLossPositionDetail">
<link:definition> 100340 - Disclosure - Investments - Summary of Gross Unrealized Losses and Fair Value of Available-For-Sale Investment Securities in Unrealized Loss Position (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfGrossUnrealizedLossesAndFairValueOfAvailableForSaleInvestmentSecuritiesInUnrealizedLossPositionParentheticalDetail" id="Role_DisclosureInvestmentsSummaryOfGrossUnrealizedLossesAndFairValueOfAvailableForSaleInvestmentSecuritiesInUnrealizedLossPositionParentheticalDetail">
<link:definition> 100350 - Disclosure - Investments - Summary of Gross Unrealized Losses and Fair Value of Available-For-Sale Investment Securities in Unrealized Loss Position (Parenthetical) (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsOfCashEquivalentsAvailableForSaleInvestmentSecuritiesAndEquitySecuritiesDetail" id="Role_DisclosureFairValueMeasurementsFairValueMeasurementsOfCashEquivalentsAvailableForSaleInvestmentSecuritiesAndEquitySecuritiesDetail">
<link:definition> 100360 - Disclosure - Fair Value Measurements - Fair Value Measurements of Cash Equivalents, Available-For-Sale Investment Securities and Equity Securities (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
<link:definition> 100370 - Disclosure - Stockholders' Equity - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition> 100380 - Disclosure - Commitments and Contingencies - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
<link:definition> 100390 - Disclosure - Leases - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseCostsDetail" id="Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetail">
<link:definition> 100400 - Disclosure - Leases - Summary of Operating Lease Costs (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToCompanySLeasesDetail" id="Role_DisclosureLeasesSupplementalCashFlowInformationRelatedToCompanySLeasesDetail">
<link:definition> 100410 - Disclosure - Leases - Supplemental Cash Flow Information Related to the Company's Leases (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetClassificationOfLeaseLiabilitiesDetail" id="Role_DisclosureLeasesSummaryOfBalanceSheetClassificationOfLeaseLiabilitiesDetail">
<link:definition> 100420 - Disclosure - Leases - Summary of Balance Sheet Classification of Lease Liabilities (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" id="Role_DisclosureLeasesSummaryOfMaturitiesOfLeaseLiabilitiesDetail">
<link:definition> 100430 - Disclosure - Leases - Summary of Maturities of Lease Liabilities (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.acadia-pharm.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfLeaseLiabilitiesDetail2" id="Role_DisclosureLeasesSummaryOfMaturitiesOfLeaseLiabilitiesDetail2">
<link:definition> 100440 - Disclosure - Leases - Summary of Maturities of Lease Liabilities (Detail)2 </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element id="acad_EquitySecuritiesFvNiUnrealizedGains" name="EquitySecuritiesFvNiUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="acad_EquitySecuritiesFvNiUnrealizedLosses" name="EquitySecuritiesFvNiUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains" name="DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="acad_DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses" name="DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_DebtSecuritiesAndEquitySecuritiesFvNi" name="DebtSecuritiesAndEquitySecuritiesFvNi" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="acad_LicenseFeesAndRoyaltyExpense" name="LicenseFeesAndRoyaltyExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_IncreaseDecreaseInOperatingLeaseAssets" name="IncreaseDecreaseInOperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="acad_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_RiskAndUncertaintiesPolicyTextBlock" name="RiskAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_LicenseFeesAndRoyaltiesPolicyTextBlock" name="LicenseFeesAndRoyaltiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_ScheduleOfSupplementalCashFlowRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowRelatedToLeasesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_LesseeOperatingLeaseLiabilityTableTextBlock" name="LesseeOperatingLeaseLiabilityTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_RegulatoryMilestonePayment" name="RegulatoryMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="acad_AccruedClinicalDevelopmentServicesCurrent" name="AccruedClinicalDevelopmentServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="acad_AccruedSalesAllowancesCurrent" name="AccruedSalesAllowancesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="acad_DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost" name="DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwo" name="AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_AvailableForSaleInvestmentSecuritiesContractualMaturityDates" name="AvailableForSaleInvestmentSecuritiesContractualMaturityDates" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_CersciTherapeuticsMember" name="CersciTherapeuticsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_OptionToPurchaseAdditionalSharesMember" name="OptionToPurchaseAdditionalSharesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_PaymentOfRoyaltyPercentageOnNetProductSales" name="PaymentOfRoyaltyPercentageOnNetProductSales" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_ObligationExpirationYear" name="ObligationExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_ExclusivityDeedMember" name="ExclusivityDeedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_NeurenPharmaceuticalsLimitedMember" name="NeurenPharmaceuticalsLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_LicenseAgreementsMember" name="LicenseAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_DevelopmentCommercializationAndSalesMilestonesMember" name="DevelopmentCommercializationAndSalesMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_CorporateCreditCardProgramMember" name="CorporateCreditCardProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_FleetProgramMember" name="FleetProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_PaymentsForExclusiveRight" name="PaymentsForExclusiveRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_SubscriptionOfShares" name="SubscriptionOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="acad_CollaborativeArrangementsUpfrontLicenseFee" name="CollaborativeArrangementsUpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_CollaborativeArrangementsUpfrontPayment" name="CollaborativeArrangementsUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_CollaborativeArrangementsUpfrontConsiderationAndTransactionPayment" name="CollaborativeArrangementsUpfrontConsiderationAndTransactionPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_CollaborativeArrangementsNonCashUpfrontPayment" name="CollaborativeArrangementsNonCashUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_CollaborativeArrangementsUpfrontPaymentDescription" name="CollaborativeArrangementsUpfrontPaymentDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_CollaborativeArrangementsUpfrontPaymentSharesIssued" name="CollaborativeArrangementsUpfrontPaymentSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="acad_CompensationExpenseRelatedToMergersToFormerHolders" name="CompensationExpenseRelatedToMergersToFormerHolders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" name="CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_NumberOfRenewalOptionTerms" name="NumberOfRenewalOptionTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="acad_CorporateOfficeSpaceLeaseAgreementMember" name="CorporateOfficeSpaceLeaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_OperatingLeaseLiabilitiesAbstract" name="OperatingLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="acad_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" name="LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="acad_CapitalizationOfRightOfUseAsset" name="CapitalizationOfRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="acad_CapitalizationOfLeaseLiability" name="CapitalizationOfLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Acadia Pharmaceuticals Inc.       10-K       12/31/23   88:14M                                    Donnelley … Solutions/FA
 2/28/23  Acadia Pharmaceuticals Inc.       10-K       12/31/22   79:15M                                    Donnelley … Solutions/FA
 3/01/22  Acadia Pharmaceuticals Inc.       10-K       12/31/21   82:13M                                    Donnelley … Solutions/FA
 2/25/21  Acadia Pharmaceuticals Inc.       10-K       12/31/20   80:13M                                    ActiveDisclosure/FA

4 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/27/19  Acadia Pharmaceuticals Inc.       10-K       12/31/18   71:13M                                    ActiveDisclosure/FA
 8/06/15  Acadia Pharmaceuticals Inc.       10-Q        6/30/15   43:1.7M                                   Donnelley … Solutions/FA
 9/12/13  Acadia Pharmaceuticals Inc.       8-K:5       9/06/13    2:179K                                   SEC Connect
12/21/00  Acadia Pharmaceuticals Inc.       S-1                   28:1.7M                                   Toppan Merrill-FA2/FA
↑Top
Filing Submission 0001564590-20-050566   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 2, 11:41:59.2am ET